You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512.HK):新型MRA藥物依普利酮片獲頒發藥品註冊證書
格隆匯 08-03 17:53

格隆匯8月3日丨遠大醫藥(00512.HK)發佈公吿,集團與南京卡文迪許生物工程技術有限公司合作的新型選擇性醛固酮受體拮抗劑(mineralocorticoid receptor antagonist,MRA)依普利酮片近日獲得中國國家藥品監督管理局頒發的藥品註冊證書。依普利酮片作為中國上市的獨家產品,其成功獲批上市彌補了中國國內二代MRA藥物的空白。

南京卡文迪許公司成立於2006年11月,是一家從事創新藥首仿開發的高新技術企業,致力於技術難度大能填補中國國內臨牀空白的新藥仿製技術的研發。南京卡文迪許公司的產品覆蓋抗腫瘤、白血病、抗厭氧菌感染、抗病毒、高血壓心衰、糖尿病等疾病治療領域。此次依普利酮片的成功上市將有望推動集團與南京卡文迪許公司後續在其他產品領域方面的深度合作。

依普利酮是一款新型的MRA藥物,可通過與醛固酮受體(mineralocorticoid receptor,MR)結合,來阻斷MR過度激活所引發的心臟病變和血管損傷。

集團一直高度重視創新產品和先進技術的研發,以患者需求為核心,以科技創新為驅動,針對尚未滿足的臨牀需求,加大對全球創新產品和先進技術的投入,豐富和完善產品管線及產業佈局,採用“全球化運營佈局,雙循環經營發展策略,形成國內國際雙循環聯動發展並相互促進的新格局,充分發揮集團的產業優勢和研發實力,快速將科技創新產品落地上市,為全球患者提供更先進更多樣的治療方案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account